Interestingly, if anemia treatment was initiated at a baseline Hb within the recommended range of 9–11 g/dL substantially more patients achieved either of these targets compared to patients who were initiated with darbepoetin alfa at a Hb value <9 g/dL. Here, GSTM1 is linked to anemia.